Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trifluoperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.96 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.96 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.96 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.96 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.78 |
| ▸ | FPR2 | P25090 | 11/20 | 0.96 |
| ▸ | LMNA | P02545 | 7/20 | 0.96 |
| ▸ | MAPT | P10636 | 7/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.96 |
| ▸ | TP53 | P04637 | 4/20 | 0.96 |
| ▸ | RAD52 | P43351 | 3/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.96 |
| ▸ | HTR1A | P08908 | 3/20 | 0.96 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.96 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.96 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoperazine SCHEMBL1897003 | 0.98 | FPR2 (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL24866 | 0.98 | FPR2 (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL29603012 | 0.98 | FPR2 (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL29430171 | 0.97 | LMNA (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL41194 | 0.97 | LMNA (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL23039392 | 0.97 | LMNA (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL341516 | 0.97 | LMNA (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL29579627 | 0.97 | LMNA (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL21445272 | 0.96 | FPR2 (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL28329317 | 0.93 | FPR2 (0.90) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| US-20160257952-A1 | IDENTIFICATION OF STRUCTURALLY SIMILAR SMALL MOLECULES THAT ENHANCE THERAPEUTIC EXON SKIPPING | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-08 | — | — | US | claimed |
| US-20110052723-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | claimed |
| WO-2010101649-A2 | SIGMA 1 RECEPTOR INHIBITION AS A NOVEL THERAPEUTICAL APPROACH AGAINST HEPATITIS C VIRUS INFECTION | GASTAMINZA PABLO (US) | 2010-09-10 | — | — | WO | claimed |
| EP-2090311-A1 | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-08-19 | — | — | EP | claimed |
| US-20090181976-A1 | Use of Compounds Binding to the Sigma Receptor for the Treatment of Metabolic Syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-07-16 | — | — | US | claimed |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | claimed |
| EP-1829534-A1 | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | claimed |
| EP-1787679-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| US-6187752-B1 | Method for treating schizophrenia employing an ace inhibitor | E.R. SQUIBB & SONS, INC. | 2001-02-13 | — | — | US | claimed |
| US-20260137707-A1 | METHODS OF MODULATING ATXN2 EXPRESSION | UNIV OF UTAH RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12508232-B2 | Pre-filling system to eliminate bubbles inside capsules having a solid dosage forms within said capsules | PROCAPS SA (CO) | 2025-12-30 | — | — | US | disclosed |
| US-20250241928-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-07-31 | — | — | US | disclosed |
| US-12280064-B2 | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomopathies | CHILDREN'S MEDICAL CENTER CORPORATION | 2025-04-22 | — | — | US | disclosed |
| US-5409710-A | Foam cell drug delivery | ENDOCON, INC. (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1994023706-A1 | FOAM CELL DRUG DELIVERY | ENDOCON, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| EP-0539059-A1 | Buoyant controlled release powder formulation | E.R. SQUIBB & SONS, INC. (US) | 1993-04-28 | — | — | EP | disclosed |
| US-5169638-A | Powder filled capsules | E. R. SQUIBB & SONS, INC. (US) | 1992-12-08 | — | — | US | disclosed |
| US-4792452-A | PH DEPENDENT POLYMER, PH INDEPENDENT HYDROCARBON GELLING AGENT AND BINDER | E. R. SQUIBB & SONS, INC. (US) | 1988-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137707-A1 | METHODS OF MODULATING ATXN2 EXPRESSION | ATXN2, ATXN2L, ATP6V1B2 | DRD2 4055/4885HTR2A 547/4885HTR2C 1301/4885 |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | OPRM1, OPRL1, OPRK1 | DRD2 240/4885HTR2A 56/4885HTR2C 70/4885 |
| US-20090181976-A1 | Use of Compounds Binding to the Sigma Receptor for the Treatment of Metabolic Syndrome | SIGMAR1, GPR119, TMEM97 | DRD2 265/4885HTR2A 28/4885HTR2C 42/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | DRD2 4171/4885HTR2A 1608/4885HTR2C 1410/4885 |
| US-20250241928-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIES | CALM1, RACK1, CAMK2B | DRD2 3379/4885HTR2A 3131/4885HTR2C 4023/4885 |
| US-12508232-B2 | Pre-filling system to eliminate bubbles inside capsules having a solid dosage forms within said capsules | KIT, PDE6G, GYS1 | DRD2 2631/4885HTR2A 758/4885HTR2C 1535/4885 |
| US-12280064-B2 | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomopathies | CALM1, RACK1, CAMK2B | DRD2 3379/4885HTR2A 3131/4885HTR2C 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.